Buy Uromitexan ampoules 400 mg, 4 ml, 15 pcs

Uromitexan® [Mesna]

Brand Baxter

In stock 989 Items

Available since: 2019-09-19

All payments are SSL encrypted
Full Refund if you haven't received your order
International shipping to the USA, UK and Europe

Clinical Pharmacology

Uromitexane has an effect that reduces the cytotoxicity of oxazaphosphorins.

Indications

Local detoxification of the urotoxic effects of cytostatics derived from oxazaphosphorins, incl. in the following cases:
- with the introduction of oxazaphosphorins in high doses (more than 10 mg / kg);
- in patients at risk - previously conducted radiation therapy on the pelvic area, the development of cystitis during the previous therapy with oxazaphosphorins, a history of urinary tract diseases.

Composition

1 amp contains mesna 400 mg; excipients: sodium edetate; sodium hydroxide; water for injections.

No customer reviews for the moment.

Write your review

Dosage and Administration

Uromitexane is administered intravenously in a jet (slowly), a single dose is 20% of a single dose of oxazaphosphorin. The first injection of Uromitexane is carried out simultaneously with the first administration of oxazaphosphorine, the second and third injections — 4 hours and 8 hours after the administration of oxazaphosphorin.
Withcontinuous infusion (24 h) of holoxane or endoxan Uromitexane should be administered at a dose of 20% of the cytostatic dose at the beginning of the infusion, then at a dose of 100% of the cytostatic dose as a 24-hour infusion, and after the introduction of the cytostatic, continue the administration of Uromitexane another 6-12 h in the same dose.

Adverse reactions

From the digestive system: nausea, vomiting, diarrhea are possible (with a single dose of more than 60 mg / kg body weight).
Other: rarely - hematuria, allergic reactions on the skin and mucous membranes.

Contraindications

Hypersensitivity to mesna or any component of uromitexane. Pregnancy and lactation period.

Drug interactions

With the simultaneous use of Uromitexan does not affect the antitumor activity of adriamycin, carmustine, cisplatin, methotrexate, vincristine, as well as the activity of cardiac glycosides.
Pharmaceutical Interaction
In aqueous solutions, Uromitexane is compatible with cyclophosphamide and ifosfamide, these drugs can be administered in the same solution, the chemical stability of the drugs is sufficient for continuous, continuous infusions.
Uromitexane should not be mixed with cisplatin in a single infusion solution, since mesna obviously inactivates cisplatin in vitro, but not in vivo, if the drugs are administered separately.

Special instructions

Uromitexan has a protective effect only on the urinary system, therefore, if it is prescribed, additional preventive measures and symptomatic therapy recommended for treatment with oxazaphosphorins should not be canceled.
During treatment with Uromitexan, false positive reactions to the presence of ketone bodies in the urine are possible. Perhaps a reddish-purple urine stain, which is unstable and immediately disappears when glacial acetic acid is added to the urine.
Uromitexane is not recommended to be administered orally for possible vomiting or emetic urging (including those that occur during treatment with cytostatics, as well as during diarrhea or surgical interventions on the gastrointestinal tract).
The results of experimental studies
Studies conducted on laboratory animals did not reveal the mutagenic action of Uromitexan.

Overdosage

During treatment, it is difficult to distinguish the effects caused by an overdose of Uromitexane from the same manifestations associated with the administration of oxazaphosphorins. It is believed that the threshold for tolerance of mesna can be exceeded with a single dose in a dose of 60-70 mg / kg. However, the toxic effects of Uromitexane in doses of 70-100 mg / kg on hematopoiesis, liver and kidney function, the CNS is not observed. The antidote of mesna is unknown.